Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831259 | 0.90 | ESR2 (0.42) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL11484818 | 0.78 | SLC18A3 (0.40) | KMT2A | |
| SCHEMBL21755529 | 0.77 | ESR2 (0.38) | ESR2DEGS1ESR1CYP3A4CYP2C9 | |
| SCHEMBL777679 | 0.76 | ATM (0.39) | KMT2AEPHX1NPC1RAB9A | |
| SCHEMBL29097668 | 0.76 | SLC18A3 (0.38) | KMT2ACYP3A4NPC1RAB9A | |
| SCHEMBL777693 | 0.75 | ALDH1A1 (0.41) | KMT2ACYP2C9CYP2D6 | |
| SCHEMBL2160450 | 0.75 | ALDH1A1 (0.41) | KMT2ACYP2C9CYP2D6 | |
| SCHEMBL2157992 | 0.75 | ALDH1A1 (0.41) | KMT2ACYP2C9CYP2D6 | |
| SCHEMBL9067822 | 0.74 | — | — | |
| SCHEMBL17090740 | 0.73 | KMT2A (0.33) | ESR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | ESR2 491/4885DEGS1 1031/4885KMT2A 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.